Back to Journals » OncoTargets and Therapy » Volume 14

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

Total article views   HTML views PDF downloads Totals
4,850 Dovepress* 4,380+ 675 5,055
PubMed Central* 470 213 683
Totals 4,850 888 5,738
*Since 20 April 2021
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar